Literature DB >> 34964999

Conditional deletion of mTOR discloses its essential role in early B-cell development.

Shuling Zhang1, Wendy Dubois1, Xingmin Feng2, Joe T Nguyen1, Neal S Young2, Beverly A Mock1.   

Abstract

Mechanistic target of rapamycin (mTOR) is a serine-threonine kinase and central regulator of cell growth, differentiation, and survival. mTOR is commonly hyperactivated in a diverse number of cancers and critical roles for mTOR in regulating immune cell differentiation and function have been demonstrated. However, there is little work investigating the roles of mTOR in early B-cell development. Here we demonstrate that conditional disruption of mTOR in developing mouse B cells results in reduced pre-B-cell proliferation and survival, as well as a developmental block at the pre-B-cell stage, with a corresponding lack of peripheral B cells. Upon immunization with NP-CGG antigen, mice with Mtor conditional disruption in early B cells lost their ability to form germinal centers and produce specific antibodies. In competitive BM repopulation assays, donor BM cells from conditional knock-out mice were completely impaired in their ability to reconstitute B cells. Our data reveal the essential role of mTOR in early pre-B-cell development and survival.
© 2021 Wiley Periodicals LLC. This article has been contributed to by US Government employees and their work is in the public domain in the USA.

Entities:  

Keywords:  B-cell development; Mb1-Cre mice; antibody production; competitive BM transplantation; mTOR

Mesh:

Substances:

Year:  2021        PMID: 34964999      PMCID: PMC8930614          DOI: 10.1002/mc.23386

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   5.139


  36 in total

1.  Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production.

Authors:  Shuling Zhang; Julie A Readinger; Wendy DuBois; Mirkka Janka-Junttila; Richard Robinson; Margaret Pruitt; Val Bliskovsky; Julie Z Wu; Kaori Sakakibara; Jyoti Patel; Carole A Parent; Lino Tessarollo; Pamela L Schwartzberg; Beverly A Mock
Journal:  Blood       Date:  2010-11-15       Impact factor: 22.113

2.  Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression.

Authors:  J Julie Wu; Jie Liu; Edmund B Chen; Jennifer J Wang; Liu Cao; Nisha Narayan; Marie M Fergusson; Ilsa I Rovira; Michele Allen; Danielle A Springer; Cory U Lago; Shuling Zhang; Wendy DuBois; Theresa Ward; Rafael deCabo; Oksana Gavrilova; Beverly Mock; Toren Finkel
Journal:  Cell Rep       Date:  2013-08-29       Impact factor: 9.423

3.  RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs.

Authors:  D M Sabatini; H Erdjument-Bromage; M Lui; P Tempst; S H Snyder
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

4.  mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells.

Authors:  Daniel Smrz; Mi-Sun Kim; Shuling Zhang; Beverly A Mock; Sárka Smrzová; Wendy DuBois; Olga Simakova; Irina Maric; Todd M Wilson; Dean D Metcalfe; Alasdair M Gilfillan
Journal:  Blood       Date:  2011-11-03       Impact factor: 22.113

Review 5.  Regulation and function of mTOR signalling in T cell fate decisions.

Authors:  Hongbo Chi
Journal:  Nat Rev Immunol       Date:  2012-04-20       Impact factor: 53.106

6.  Conditional Disruption of Raptor Reveals an Essential Role for mTORC1 in B Cell Development, Survival, and Metabolism.

Authors:  Terri N Iwata; Julita A Ramírez; Mark Tsang; Heon Park; Daciana H Margineantu; David M Hockenbery; Brian M Iritani
Journal:  J Immunol       Date:  2016-08-12       Impact factor: 5.422

7.  Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene.

Authors:  Valery Bliskovsky; Edward S Ramsay; John Scott; Wendy DuBois; Wei Shi; Shuling Zhang; Xiaolan Qian; Douglas R Lowy; Beverly A Mock
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-21       Impact factor: 11.205

8.  Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression.

Authors:  J Kunz; R Henriquez; U Schneider; M Deuter-Reinhard; N R Movva; M N Hall
Journal:  Cell       Date:  1993-05-07       Impact factor: 41.582

Review 9.  mTOR at the nexus of nutrition, growth, ageing and disease.

Authors:  Grace Y Liu; David M Sabatini
Journal:  Nat Rev Mol Cell Biol       Date:  2020-01-14       Impact factor: 94.444

10.  Functionally Distinct Subsets of Lineage-Biased Multipotent Progenitors Control Blood Production in Normal and Regenerative Conditions.

Authors:  Eric M Pietras; Damien Reynaud; Yoon-A Kang; Daniel Carlin; Fernando J Calero-Nieto; Andrew D Leavitt; Joshua M Stuart; Berthold Göttgens; Emmanuelle Passegué
Journal:  Cell Stem Cell       Date:  2015-06-18       Impact factor: 24.633

View more
  1 in total

Review 1.  Medical Aspects of mTOR Inhibition in Kidney Transplantation.

Authors:  Elena Cuadrado-Payán; Fritz Diekmann; David Cucchiari
Journal:  Int J Mol Sci       Date:  2022-07-12       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.